DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 192
- Registration Number
- NCT00403481
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 903
- Registration Number
- NCT00398216
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 210
- Registration Number
- NCT00382213
Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2008-06-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 35
- Registration Number
- NCT00361153
- Locations
- 🇺🇸
Diabetes and Glandular Research Associates, San Antonio, Texas, United States
The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2008-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 85
- Registration Number
- NCT00330135
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT00320827
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 400
- Registration Number
- NCT00290940
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 43
- Registration Number
- NCT00272909
- Locations
- 🇺🇸
The Stroke Center at Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Chattanooga Neurology Associates, Chattanooga, Tennessee, United States
🇺🇸Lakeland Regional Medical Center, Lakeland, Florida, United States
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 162
- Registration Number
- NCT00259038
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT00185068
© Copyright 2024. All Rights Reserved by MedPath